Blinatumomab 35 µg
| Product Overview | |
| Generic Name | Blinatumomab 35 µg | 
| Brand Name(s) | Blincyto | 
| Form | Intravenous lyophilized powder, single dose vial | 
| Strength | 35 µg | 
| Therapeutic Class | Antineoplastic / Immunotherapy | 
| ATC Code | L01FX07 | 
| Manufacturing & Regulatory | |
| Manufacturer | Amgen Inc. | 
| Country | India/USA | 
| GMP Compliance | WHO/cGMP-compliant | 
| DMF/CEP | Not publicly disclosed | 
| COFEPRIS | Not visible in public domain; | 
| Free Sale Certificate | Available (manufactured in US with international approvals) | 
| Logistics & Export | |
| MOQ | 5 vials | 
| Shelf Life | 24 Months | 
| Storage | Refrigerated (2–8 °C) do not freeze | 
| Incoterms | EXW/FOB/CIF negotiable | 
| Lead Time | lead times vary (2–4 weeks) | 
| Documentation | |
| Certificate of Analysis (COA) | Yes—from manufacturer | 
| SDS | available via manufacturer/distributor | 
| CTD Summary | Available under confidentiality; summary upon significant purchase | 
Description
(Indications & Usage) Blinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE) indicated for: • MRD-positive or relapsed/refractory CD19+ B‑cell precursor ALL in adults and children ≥1 month • Consolidation therapy during multi‑phase chemotherapy for Philadelphia chromosome-negative B‑ALL
 
				